Serum antibodies to microbial antigens for Crohn's disease progression: A meta-analysis

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 7, 2014, Pages 733-742

  Xiong, Yao ^a,b   Wang, Gou Zhen ^a,b   Zhou, Jie Qiong ^a,b   Xia, Bing Qing ^a,b   Wang, Xin Ying ^a,b   Jiang, Bo ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangdong Provincial Key Laboratory of Gastroenterology   (China)

Author keywords

Complication; Crohn's disease; Meta analysis; Microbial antigens; Serum antibodies; Surgery

Indexed keywords

ANTIBODY; BACTERIAL FLAGELLIN ANTIBODY; OUTER MEMBRANE PROTEIN C ANTIBODY; PSEUDOMONAS FLUORESCENS ASSOCIATED SEQUENCE 12 ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CBIR1 FLAGELLIN; FLAGELLIN; FUNGUS ANTIBODY; OUTER MEMBRANE PROTEIN C; PORIN; SACCHAROMYCES CEREVISIAE PROTEIN;

ANTIBODY BLOOD LEVEL; ARTICLE; CROHN DISEASE; DISEASE COURSE; EMBASE; HUMAN; MEDICAL SUBJECT HEADINGS; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ADULT; BLOOD; EPIDEMIOLOGY; IMMUNOLOGY; PSEUDOMONAS FLUORESCENS; YOUNG ADULT;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, FUNGAL; BACTERIAL PROTEINS; CROHN DISEASE; DISEASE PROGRESSION; FLAGELLIN; HUMANS; PORINS; PSEUDOMONAS FLUORESCENS; SACCHAROMYCES CEREVISIAE PROTEINS; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84902185925     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000102     Document Type: Article

References (59)

1. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8:244-250.
2. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54:237-241.
3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255-260.
4. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25:3-12.
5. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135:1493-1499.
6. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60:930-936.
7. Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis 2009; 15:1570-1582.
8. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130:650-656.
9. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104:371-383.
10. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical prognostic factors for disabling Crohn's disease: a systematic review and meta-Analysis. World J Gastroenterol 2013; 19:3866-3871.
11. Cerqueira RM, Lago PM. Clinical factors predictive of Crohn's disease complications and surgery. Eur J Gastroenterol Hepatol 2013; 25: 129-134.
12. Lichtenstein GR. Emerging prognostic markers to determine Crohn's disease natural history and improve management strategies: a review of recent literature. Gastroenterol Hepatol 2010; 6:99-107.
13. Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clinic Exp Gastroenterol 2011; 4:127-140.
14. Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-Analysis. Am J Gastroenterol 2011; 106:699-712.
15. Arnott IDRMD, Landers CJPD, Nimmo EJPD, Drummond HEBS, Smith BKRBS, Targan SRMD, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99:2376-2384.
16. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101:360-367.
17. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394-1403.
18. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126:414-424.
19. Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/ CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis 2007; 13:984-992.
20. Zholudev A, Young WB, Leichtner AM, Bousvaros A. Sensitivity and specificity of p-ANCA, ASCA, and anti-OmpC serologic testing for inflammatory bowel disease in children and young adults. Gastroenterology 2002; 122:A12-A12.
21. Dotan N, Altstock RT, Schwarz M, Dukler A. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus 2006; 15:442-450.
22. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988; 297:1105-1106.
23. Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 2007; 23:16-20.
24. Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-Associated I2 sequence and T-cell superantigen. Infect Immun 2002; 70:6567-6575.
25. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113:1296-1306.
26. Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012; 18:1340-1355.
27. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6:1105-1111.
28. Elkadri AA, Stempak JM,Walters TD, Lal S, Griffiths AM, Steinhart AH, et al. Serum antibodies associated with complex inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:1499-1505.
29. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140:1817-1826.e2.
30. Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S, et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-Analysis. Dig Dis Sci 2012; 57:2944-2954.
31. Kaul A, Hutfless S, Liu L, Bayless TM, Marohn MR, Li X. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-Analysis. Inflamm Bowel Dis 2012; 18:1872-1884.
32. Whiting PF,Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6:9.
33. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-Analysis of test accuracy data. BMC Med Res Methodol 2006; 6:31.
34. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002; 2:9.
35. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
36. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58:882-893.
37. O'Donnell S, O'Sullivan M, O'Morain CA, Ryan BM. The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population. Eur J Gastroenterol Hepatol 2013; 25:1464-1469.
38. Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007; 13:524-530.
39. Ryan JD, Silverberg MS, Xu W, Graff LA, Targownik LE, Walker JR, et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 2013; 38:274-283.
40. Suzuki H, Fukuda Y, Koizuka H, Tomita T, Hori K, Suzuki M, et al. Dietary antigens in Crohn's disease: antibodies to porcine pancreatic amylase. Am J Gastroenterol 2008; 103:656-664.
41. Michielan A, Basso D, Martinato M, Pathak S, Banerjee A, Oliva L, et al. Increased antibody response to microbial antigens in patients with Crohn's disease and their unaffected first-degree relatives. Dig Liver Dis 2013; 45:894-898.
42. Papp M, Norman GL, Vitalis Z, Tornai I, Altorjay I, Foldi I, et al. Presence of anti-microbial antibodies in liver cirrhosis-A tell-tale sign of compromised immunity? PloS One 2010; 5:e12957.
43. Kamat A, Ancuta P, Blumberg RS, Gabuzda D. Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation. PLoS One 2010; 5:e15533.
44. Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F, et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011; 17:2488-2496.
45. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, et al. Selected loss of tolerance evidenced by Crohn's disease-Associated immune responses to auto-And microbial antigens. Gastroenterology 2002; 123:689-699.
46. Muller S, Styner M, Seibold-Schmid B, Flogerzi B, Mahler M, Konrad A, et al. Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. World J Gastroenterol 2005; 11:6988-6994.
47. Eser A, Papay P, Primas C, Pernicka E, Harrer M, Dejaco C, et al. The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease. Aliment Pharmacol Ther 2012; 35:292-299.
48. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128:2020-2028.
49. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006; 101:645-652.
50. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD Cohort. Am J Gastroenterol 2008; 103:665-681.
51. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing shortterm and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17:1451-1457.
52. Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002; 97:1458-1462.
53. Papp M, Foldi I, Altorjay I, Palyu E, Udvardy M, Tumpek J, et al. Anti-microbial antibodies in celiac disease: trick or treat? World J Gastroenterol 2009; 15:3891-3900.
54. van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2013; 62:683-688.
55. Harrer M, ReinischW, Dejaco C, Kratzer V, Gmeiner M, MiehslerW, et al. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol 2003; 15:1281-1285.
56. Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001; 7:8-15.
57. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999; 11:648-656.
58. De Winter H, Cheroutre H, Kronenberg M. Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: pathogenic and protective roles in a mouse colitis model. Am J Physiol 1999; 276:G1317-G1321.
59. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20:495-549.